Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat sodium in ultra-early moderately severe acute pancreatitis with SIRS
ChiCTR2500106233Phase 4Not yet recruiting
- Sponsor
- Ganzhou People's Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sivelestat in acute pancreatitis (AP) and Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by Ganzhou People's Hospital. Primary endpoint: Change in SOFA score from baseline. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
acute pancreatitis (AP)Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on ChiCTR2500106233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106233.